Nov 9 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP REPORTS IMPROVED AND STATISTICALLY SIGNIFICANT SURVIVAL BENEFIT FOR THREE KEY PATIENT GROUPS IN FINAL PHASE IIB AIPAC STUDY RESULTS IN METASTATIC BREAST CANCER
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $366.9M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 25.0¢ | $537.6K | 2.121M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40101 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 297079 | 7 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |